Does VEDOLIZUMAB Cause Hypercholesterolaemia? 304 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 304 reports of Hypercholesterolaemia have been filed in association with VEDOLIZUMAB (ENTYVIO). This represents 0.4% of all adverse event reports for VEDOLIZUMAB.
304
Reports of Hypercholesterolaemia with VEDOLIZUMAB
0.4%
of all VEDOLIZUMAB reports
283
Deaths
173
Hospitalizations
How Dangerous Is Hypercholesterolaemia From VEDOLIZUMAB?
Of the 304 reports, 283 (93.1%) resulted in death, 173 (56.9%) required hospitalization, and 171 (56.3%) were considered life-threatening.
Is Hypercholesterolaemia Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for VEDOLIZUMAB. However, 304 reports have been filed with the FAERS database.
What Other Side Effects Does VEDOLIZUMAB Cause?
Off label use (21,017)
Colitis ulcerative (13,455)
Crohn's disease (9,759)
Drug ineffective (8,424)
Diarrhoea (7,493)
Abdominal pain (6,401)
Fatigue (5,477)
Haematochezia (5,215)
Frequent bowel movements (4,527)
Arthralgia (4,028)
What Other Drugs Cause Hypercholesterolaemia?
ALENDRONATE (1,607)
METHOTREXATE (1,547)
TOCILIZUMAB (1,483)
ADALIMUMAB (1,479)
ABATACEPT (1,410)
RITUXIMAB (1,389)
PREDNISONE (1,377)
INFLIXIMAB (1,338)
DICLOFENAC (1,331)
LEFLUNOMIDE (1,322)
Which VEDOLIZUMAB Alternatives Have Lower Hypercholesterolaemia Risk?
VEDOLIZUMAB vs VELAGLUCERASE ALFA
VEDOLIZUMAB vs VELCADE
VEDOLIZUMAB vs VELETRI
VEDOLIZUMAB vs VELIPARIB
VEDOLIZUMAB vs VEMURAFENIB